Published in Ther Adv Musculoskelet Dis on April 01, 2009
Current perspectives on bisphosphonate treatment in Paget's disease of bone. Ther Clin Risk Manag (2014) 0.79
Molecular genetics of osteosarcoma. Bone (2016) 0.75
An Insight in to Paget's Disease of Bone. Niger J Surg (2014) 0.75
Epidemiology and pathology of Paget's disease of bone - a review. Wien Med Wochenschr (2016) 0.75
Osteoclast differentiation and activation. Nature (2003) 18.59
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab (2004) 8.36
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet (2004) 7.84
Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med (2006) 7.46
Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 7.09
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76
Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med (2008) 4.81
Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br (2007) 4.10
Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int (2008) 3.80
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury (2008) 3.50
Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med (2002) 3.34
Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet (2002) 3.00
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res (2009) 2.65
Guidelines on the management of Paget's disease of bone. Bone (2002) 2.34
Detection of measles virus nucleocapsid transcripts in circulating blood cells from patients with Paget disease. J Bone Miner Res (1996) 2.33
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet (2000) 2.13
Paget's disease in an archeological population. J Bone Miner Res (2002) 2.05
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med (1996) 2.00
Alendronate and atrial fibrillation. N Engl J Med (2007) 2.00
Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab (2008) 1.99
Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med (2005) 1.99
Paget disease of bone. J Clin Invest (2005) 1.92
On a Form of Chronic Inflammation of Bones (Osteitis Deformans). Med Chir Trans (1877) 1.90
Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest (1992) 1.78
Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet (2002) 1.72
Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res (2002) 1.66
Canine distemper virus transcripts sequenced from pagetic bone. Bone Miner (1992) 1.59
Nuclear inclusions in Paget's disease of bone. Science (1976) 1.57
Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (2008) 1.54
More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 1.50
Neurologic disturbances in Paget disease of bone: response to calcitonin. Neurology (1979) 1.48
Bisphosphonate resistance in Paget's disease of bone. Arthritis Rheum (2003) 1.45
Intravenously administered pamidronate in the treatment of Paget's disease of bone. Endocr Pract (2001) 1.40
Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc (2009) 1.39
A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet (2008) 1.33
Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother (2005) 1.33
The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum (2001) 1.31
More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 1.31
Musculoskeletal manifestations of Paget's disease of bone. Arthritis Rheum (1980) 1.29
Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest (2000) 1.29
Osteosarcoma in Paget's disease of bone. J Bone Miner Res (2006) 1.27
Familial aggregation of Paget's disease of bone. J Bone Miner Res (1991) 1.26
More on atypical fractures of the femoral diaphysis. N Engl J Med (2008) 1.21
Pathogenesis and management of Paget's disease of bone. Lancet (2008) 1.21
Clinical practice. Paget's disease of bone. N Engl J Med (2006) 1.19
Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res (2002) 1.19
Measles virus RNA detected in Paget's disease bone tissue by in situ hybridization. J Gen Virol (1986) 1.18
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res (2007) 1.16
Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet (2007) 1.16
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab (1996) 1.15
Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res (2003) 1.14
Contribution of genetic factors to the pathogenesis of Paget's disease of bone and related disorders. J Bone Miner Res (2006) 1.14
Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. Am J Hum Genet (2001) 1.14
The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res (1999) 1.14
A probable linkage between familial Paget's disease and the HLA loci. Aust N Z J Med (1982) 1.12
Paget disease of bone: mapping of two loci at 5q35-qter and 5q31. Am J Hum Genet (2001) 1.12
Interleukin-6, IL-6 receptor, and IL-6 nuclear factor gene expression in Paget's disease. J Bone Miner Res (1994) 1.11
A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med (1988) 1.09
Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest (2000) 1.09
Bone marrow mononuclear cells from patients with Paget's disease contain measles virus nucleocapsid messenger ribonucleic acid that has mutations in a specific region of the sequence. J Clin Endocrinol Metab (1995) 1.09
The mechanism of hearing loss in Paget's disease of bone. Laryngoscope (2004) 1.08
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med (1999) 1.08
A negative search for a paramyxoviral etiology of Paget's disease of bone: molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res (2000) 1.07
Canine distemper virus localised in bone cells of patients with Paget's disease. Bone (1991) 1.06
Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone (2001) 1.05
A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res (2001) 1.04
Genetic linkage of Paget disease of the bone to chromosome 18q. Am J Hum Genet (1997) 1.03
Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res (1998) 1.02
The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. Mol Endocrinol (2009) 1.01
Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res (1998) 1.00
Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int (2007) 1.00
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone (2004) 0.99
Prevalence of Paget's disease of bone in Italy. J Bone Miner Res (2005) 0.99
Update on the epidemiology of Paget's disease of bone. J Bone Miner Res (2006) 0.99
Paget disease of bone: therapeutic options. J Clin Rheumatol (2008) 0.98
Pathogenesis of Paget's disease of bone. Bone (2008) 0.98
Autosomal dominant inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Alzheimer Dis Assoc Disord (2005) 0.97
Denosumab: anti-RANKL antibody. Curr Osteoporos Rep (2009) 0.96
Paget's disease in New Zealand: evidence for declining prevalence. Bone (2002) 0.96
Identification of a major locus for Paget's disease on chromosome 10p13 in families of British descent. J Bone Miner Res (2008) 0.94
Failure to detect paramyxovirus sequences in Paget's disease of bone using the polymerase chain reaction. J Bone Miner Res (1991) 0.94
Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone. J Bone Miner Res (2009) 0.94
Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res (1995) 0.93
Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int (2009) 0.93
Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United States. Calcif Tissue Int (2008) 0.92
Morbidity and mortality associated with Paget's disease of bone: a population-based study. J Bone Miner Res (2008) 0.92
Paget's disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int (2004) 0.91
Long-term trends in the incidence of Paget's disease of bone. Bone (2000) 0.91
Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet (2001) 0.91
Detection of canine distemper virus in 100% of Paget's disease samples by in situ-reverse transcriptase-polymerase chain reaction. Bone (1998) 0.90
Alendronate-induced synovitis. J Rheumatol (2008) 0.90
Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J Bone Miner Res (2006) 0.90
Absence of somatic SQSTM1 mutations in Paget's disease of bone. J Clin Endocrinol Metab (2008) 0.90
Goals of treatment for Paget's disease of bone. J Bone Miner Res (1999) 0.89
Extraskeletal osteoclastomas responsive to dexamethasone treatment in Paget bone disease. J Clin Endocrinol Metab (1997) 0.89
Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy. J Bone Miner Res (2006) 0.88
Paget's disease of bone in Italy. J Bone Miner Res (2006) 0.88
Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab (2006) 1.91
Evolution of a pheochromocytoma. Endocr Pract (2006) 1.39
Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab (2006) 1.17
Successful treatment of tumor-induced osteomalacia with CT-guided percutaneous ethanol and cryoablation. J Clin Endocrinol Metab (2012) 1.00
PTHrP during petrosal sinus sampling. Clin Endocrinol (Oxf) (2002) 0.75
Artifactual reduction in bone density as a result of technetium-99m MDP for bone scanning: report of two cases. J Clin Densitom (2004) 0.75